**A Quick Look at Using Meningococcal Serogroup B Vaccines (MenB)**

**Indications for use and schedule**
- **Trumenba®** (MenB-FHbp) for persons 10 years & older
  - 3 dose series at 0, 1-2, 6 months for persons at increased risk or within an outbreak
  - If the 2nd dose is administered earlier than 6 months after the 1st dose, a 3rd dose should be administered at least 4 months after the 2nd dose
- **Bexsero®** (MenB-4C) for persons 10 years & older
  - 2 dose series at 0, 1 month after 1st dose

**Vaccine Administration**
- Intramuscular (IM) injection in the deltoid of the arm
  - 1-1.5 inch, 22-25 gauge needle
  - Use professional judgement in selecting needle length
- Can be given simultaneously with other vaccines, including Meningococcal Conjugate vaccine (MenACWY)
  - Use different anatomical sites if possible
- The same MenB vaccine brand must be used for all doses to complete the series
  - Complete a series with 1 or the other vaccine; if a person has already received 1 dose of Bexsero and 1 of Trumenba, pick a brand and finish a recommended schedule with that brand; the next dose of the brand you pick should be separated by a minimum of 1 month after the last MenB dose (www.immunize.org/askexperts)

**Indications for Use**

**Routine Use (Category A)**
Vaccinate persons 10 years and older who are at increased risk for meningococcal disease:
- Anatomic or functional asplenia, including sickle cell disease
- Persistent complement component deficiencies
  - Including inherited or chronic deficiencies in C3, C5-C9, properdin, factor H, factor D or taking eculizumab [Soliris®]
- Microbiologists routinely exposed to isolates of *Neisseria meningitidis*
- Exposure during a community outbreak attributable to serogroup B

**Discuss and/or Give MenB vaccine (Category B)**
- Based on provider clinical decision, persons 16 through 23 years without high risk conditions may receive either vaccine for short-term protection against most strains of serogroup B disease
  - Preferred age is 16 through 18 years

**Storage and Handling**
- Store in the refrigerator unit between 36º-46ºF (2º-8ºC)
  - Stand-alone purpose built units are preferred
  - Do not freeze (discard if frozen)
- Keep in original box
- Bexsero® and Trumenba® supplied as 0.5 mL single-dose pre-filled syringe
  - Shake prefilled syringes well before use
- Protect Bexsero® from light
- Lay Trumenba® syringes flat on shelf

**Additional Vaccine Recommendation Points**
- Category A and B immunization recommendations: the Advisory Committee on Immunization Practices (ACIP) designates vaccine recommendations as either category A or category B
  - Category A (Cat. A) recommendations are made for all persons in an age or risk factor group
  - Category B (Cat. B) recommendations are made for individual clinical decision making
  - Meningococcal serogroup B vaccines have both a category A and a category B recommendation; the category B recommendation is for persons 16 through 23 years of age

---

Rev. January 23, 2018
Michigan Department of Health and Human Services – Division of Immunization
• Based on provider clinical decision a person 16 through 23 years of age may receive either MenB vaccine for short-term protection after a discussion has occurred regarding the benefit of vaccine and the risk of disease
- Category A & B recommendations are covered under the Vaccines for Children (VFC) program and under the Affordable Care Act (ACA)

Contraindications
• An anaphylactic (severe allergic) reaction to a prior dose or a component of MenB vaccines

Precautions
• Moderate to severe acute illness
• Bexsero® pre-filled syringes contain natural rubber latex in caps; may cause allergic reactions in latex sensitive individuals

Further Points
• Children less than age 10 years are not recommended to receive either vaccine, regardless of risk condition(s)
• Unlike Meningococcal Conjugate Vaccines (MenACWY), MenB vaccines are not routinely recommended for adolescents aged 10 through 15 years without a risk condition, first-year college students living in residence halls, military recruits and international travelers
• There is no preference for the use of one brand of MenB vaccine over the other
• MenB vaccine should be deferred during pregnancy and should be used only if clearly needed
• Meningococcal serogroup B Vaccine Information Statement (VIS), including information about the Michigan Care Improvement Registry (MCIR), can be found at www.michigan.gov/immunize or your local health department
• Meningococcal serogroup B vaccines in MCIR:
  - MenB vaccine will be forecasted as a general routine vaccine series for persons 16 through 23 years of age with a due date of the 16th birthday
  - MenB vaccine will display on the MCIR information screen as “MenB Cat. B”, and under the status column “Discuss/Due Now” will be displayed. On the Immunization Status page it will be displayed as “MenB Category B with Discuss/Due Now”
  - Once dose 1 is given, the vaccine brand will be displayed as MenB-4C (Bexsero) or MenB-FHbp (Trumenba); MCIR will forecast dose 2 at the appropriate interval as DUE based on what MenB vaccine brand was given
  - If both MenB vaccine brands have been given as dose 1 and dose 2, MCIR will forecast the final MenB dose based on the last dose that was given
  - MCIR will display doses given at 10 years and older under Other Administrations -there is no second dose forecasting for this age group at this time (MCIR will not forecast for patients with high risk indications)
• Document Bexsero® as “MenB-4C (Bexsero)” & Trumenba® as “MenB-FHbp (Trumenba)” in MCIR and as “MenB (Bexsero)” and “MenB (Trumenba)” on the vaccine administration record (VAR) & immunization record card
• For information regarding meningococcal conjugate vaccine (MenACWY) refer to the Meningococcal Conjugate Quick Look at www.michigan.gov/immunize under “Health Care Providers/Professionals” and to the Meningococcal Conjugate vaccine recommendations at www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html
• For further information regarding meningococcal vaccines refer to the CDC website “Meningococcal Vaccination for Adolescents: Information for Healthcare Professionals” at www.cdc.gov/vaccines/vpd/ mening/hcp/adolescent-vaccine.html

Publicly purchased MenB vaccine can be administered to eligible children aged 10 through 18 years with an indication for vaccination through the Vaccines for Children (VFC) Program in private providers’ offices. Eligible children include those who are uninsured, underinsured, Medicaid eligible, Native American or Alaskan Natives. Contact your local health department for more information.
Resource: “Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine”, May 19, 2017, “Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults”, 10/23/15 and “Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk”, 06/12/15, recommendations of the ACIP located at www.cdc.gov/vaccines/recs. Updates to this Quick Look handout will be posted at www.michigan.gov/immunize under “Provider Information”